Meeting NewsVideo

VIDEO: New treatment option for rare cardiomyopathy may 'change lives'

MUNICH — In this Cardiology Today video exclusive, Martha Gulati, MD, MS, FACC, FAHA, offers her highlights from the European Society of Cardiology Congress, including the ATTR-ACT and SCOT-HEART trials.

ATTR-ACT, which showed tafadamis (Pfizer) improved outcomes in patients with certain types of transthyretin amyloid cardiomyopathy, is the trial from ESC Congress “that I think is going to change lives the most,” Gulati, division chief of cardiology for the University of Arizona College of Medicine – Phoenix and physician executive director for the Banner – University Medicine Heart Institute, told Cardiology Today.

Gulati also provides her insight on the SCOT-HEART trial, which showed that patients with stable chest pain who underwent CTA with standard care had lower CV outcomes at 5 years compared with standard care alone.

“This is a controversial study that we’ll keep discussing,” she said.

Watch the video for more.

MUNICH — In this Cardiology Today video exclusive, Martha Gulati, MD, MS, FACC, FAHA, offers her highlights from the European Society of Cardiology Congress, including the ATTR-ACT and SCOT-HEART trials.

ATTR-ACT, which showed tafadamis (Pfizer) improved outcomes in patients with certain types of transthyretin amyloid cardiomyopathy, is the trial from ESC Congress “that I think is going to change lives the most,” Gulati, division chief of cardiology for the University of Arizona College of Medicine – Phoenix and physician executive director for the Banner – University Medicine Heart Institute, told Cardiology Today.

Gulati also provides her insight on the SCOT-HEART trial, which showed that patients with stable chest pain who underwent CTA with standard care had lower CV outcomes at 5 years compared with standard care alone.

“This is a controversial study that we’ll keep discussing,” she said.

Watch the video for more.

    See more from European Society of Cardiology Congress